The selective p19 interleukin (IL)-23 blocker guselkumab (Tremfya) was safe and reduced disease activity in adults with moderate to severe Crohn's disease who had an inadequate response to prior ...

In a previous video, investigator Jessica Allegretti, MD, of the Crohn's and Colitis Center at Brigham and Women's Hospital in Boston, discussed the results from the QUASAR phase III induction study ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...

Please provide your email address to receive an email when new articles are posted on . Guselkumab dosing every 16 weeks was noninferior to dosing every 8 weeks for maintaining psoriasis disease ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Guselkumab in combination with golimumab induced greater rates of clinical remission compared ...

Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study. Guselkumab demonstrated ...

According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better ...